Some state policies may not protect Medicaid drug selection decisions against conflicts of interests and industry influence, according to a study published today by JAMA Internal Medicine.
The study's authors found that conflict-of-interest policies vary among the state committees that make decisions about what drugs are included on a state's formulary.
Thirty-three percent of the states had written policies, while seven states did not address conflicts of interest at all in their drug-selection policy documents. The most common management strategy among states was to require committee members to disclose possible conflicts of interests to committee administrators. About two-thirds of states currently have this requirement.